About Seaport Therapeutics
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines.
The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform.
The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects.
All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines.
The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors.
The company was founded in 2024 and is based in Boston, Massachusetts.